Pharma companies need to limit the presence of nitrosamines in human medicines: EMA
Patients should generally not be exposed to a lifetime risk of cancer exceeding 1 in 100,000 from nitrosamines in their medicines
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Home » EU
Browsing Tag
EU
Faulty Medical Devices: A Value Chain gone Berserk?
Prashant K Singh, Director, Coordination and Strategy Development, at the Public Health Foundation of India. expounds on how…